Literature DB >> 11534262

Antiphospholipid antibodies and the endothelium.

P L Meroni1, E Raschi, C Testoni, A Tincani, G Balestrieri.   

Abstract

The interaction between aPL (particularly anti-beta 2GPI antibodies) and endothelium does represent a potential pathogenetic mechanism for the thrombotic manifestations of the syndrome. The autoantibody-mediated EC activation probably plays a role in sustaining the appearance of a proadhesive, proinflammatory, and procoagulant phenotype. The heterogeneity of the APS clinical manifestations is likely linked to the varied effects that aPL can induce on ECs and to the different functions that ECs display depending on the anatomic localization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11534262     DOI: 10.1016/s0889-857x(05)70222-2

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  10 in total

1.  Spontaneous renal artery dissection.

Authors:  Santhosh G John; Unnikrishnan Pillai; Philip B Vaidyan; Takaaki Ishiyama
Journal:  Mo Med       Date:  2010 Mar-Apr

2.  Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography.

Authors:  Erick Alexanderson; Patricio Cruz; Angélica Vargas; Aloha Meave; Alejandro Ricalde; Jose A Talayero; José Luis Romero-Ibarra; Tovë M Goldson; Olga L Vera-Lastra; Gabriela Medina; Luis Jara; Mary-Carmen Amigo
Journal:  J Nucl Cardiol       Date:  2007-07-02       Impact factor: 5.952

Review 3.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

Review 4.  Can rheumatoid arthritis be prevented?

Authors:  Kevin D Deane
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-10-02       Impact factor: 4.098

5.  Spontaneous coronary artery dissection in the postpartum period: association with antiphospholipid antibody.

Authors:  M Krishnamurthy; R Desai; H Patel
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

Review 6.  Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.

Authors:  Kevin D Deane; Hani El-Gabalawy
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

Review 7.  Pathogenic mechanisms of anti-endothelial cell antibodies (AECA): their prevalence and clinical relevance.

Authors:  Cristiano Alessandri; Michele Bombardieri; Guido Valesini
Journal:  Adv Clin Chem       Date:  2006       Impact factor: 5.394

Review 8.  Antiphospholipid antibodies: paradigm in transition.

Authors:  Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2009-01-20       Impact factor: 8.322

Review 9.  Antiphospholipid syndrome.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Arthritis Res Ther       Date:  2008-12-15       Impact factor: 5.156

10.  Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study.

Authors:  Carlos J Bidot; Lawrence L Horstman; Wenche Jy; Joaquin J Jimenez; Carlos Bidot; Yeon S Ahn; J Steven Alexander; Eduardo Gonzalez-Toledo; Roger E Kelley; Alireza Minagar
Journal:  BMC Neurol       Date:  2007-10-18       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.